Tissue Factor Pathway Inhibitor in Childhood Nephrotic Syndrome

Overview

Journal Pediatr Nephrol

Specialties Nephrology
Pediatrics

Date 2006 Apr 1

PMID 16575589

Citations 6

Authors

Mohamed M Al-Mugeiren

Abdel Galil M Abdel Gader

Saud A Al-Rasheed

Abdullah A Al-Salloum

Affiliations

Soon will be listed here.

Abstract

It is now recognised that the extrinsic tissue factor pathway is the main trigger to the coagulation system in vivo. Its main inhibitor, tissue factor pathway inhibitor (TFPI), has never been studied in childhood nephrotic syndrome. The aim of the study was to monitor the level of TFPI in childhood nephrotic syndrome. One hundred and thirty-nine nephrotic children were classified into the following groups: group 1 (n=25), in relapse and receiving no treatment; group 2 (n=37), in relapse but receiving steroid treatment; group 3 (n= 45), in early remission and on steroids; group 4 (n=24), in established remission and receiving no steroids; group 5 (n=8), steroid-resistant. The controls (n=84) were healthy and age-matched. There was significant elevation of total TFPI levels in groups 1 and 2 and 3; levels were comparable to those of the healthy controls in group 4. The highest levels of total TFPI were recorded in group 5. Like total TFPI, the levels of the free form of TFPI showed a statistically significant increase in groups 1, 2, 3 and 4, when compared with levels in healthy controls. The highest levels of free TFPI were recorded group 5. We concluded that the elevated levels of both the total and free TFPI in various phases of nephrotic syndrome add another natural anticoagulant mechanism, which will attenuate the hypercoagulability of childhood nephrotic syndrome.

Citing Articles

Long Non-Coding RNAs in Venous Thromboembolism: Where Do We Stand?.

Marques I, Tavares V, Neto B, Mota I, Pereira D, Medeiros R Int J Mol Sci. 2023; 24(15).

PMID: 37569483 PMC: 10418965. DOI: 10.3390/ijms241512103.

Nephrotic syndrome-associated hypercoagulopathy is alleviated by both pioglitazone and glucocorticoid which target two different nuclear receptors.

Waller A, Agrawal S, Wolfgang K, Kino J, Chanley M, Smoyer W Physiol Rep. 2020; 8(15):e14515.

PMID: 32776495 PMC: 7415912. DOI: 10.14814/phy2.14515.

Heparanase and coagulation-new insights.

Nadir Y Rambam Maimonides Med J. 2014; 5(4):e0031.

PMID: 25386347 PMC: 4222420. DOI: 10.5041/RMMJ.10165.

Primary Nephrotic Syndrome in Adults as a Risk Factor for Pulmonary Embolism: An Up-to-Date Review of the Literature.

Mirrakhimov A, Ali A, Barbaryan A, Prueksaritanond S, Hussain N Int J Nephrol. 2014; 2014:916760.

PMID: 24829800 PMC: 4009182. DOI: 10.1155/2014/916760.

Heparanase-A Link between Coagulation, Angiogenesis, and Cancer.

Nadir Y, Brenner B Rambam Maimonides Med J. 2013; 3(1):e0002.

PMID: 23908827 PMC: 3707414. DOI: 10.5041/RMMJ.10069.

References

DAngelo A, Kaufman Jr C, Sholer C, Esmon C, Comp P . Protein S deficiency occurs in the nephrotic syndrome. Ann Intern Med. 1987; 107(1):42-7. DOI: 10.7326/0003-4819-107-1-42. View

Novotny W, Brown S, Miletich J, Rader D, Broze Jr G . Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood. 1991; 78(2):387-93. View

Morishita E, Asakura H, Saito M, Yamazaki M, Ontachi Y, Mizutani T . Elevated plasma levels of free-form of TFPI antigen in hypercholesterolemic patients. Atherosclerosis. 2001; 154(1):203-12. DOI: 10.1016/s0021-9150(00)00463-9. View

Malyszko J, Malyszko J, Mysliwiec M . [Tissue factor and inhibitor of the blood coagulation pathway in nephrotic syndrome]. Pol Arch Med Wewn. 2000; 101(4):301-5. View

Yermiahu T, Shalev H, Landau D, Dvilansky A . Protein C and protein S in pediatric nephrotic patients. Sangre (Barc). 1996; 41(2):155-7. View

Al-Mugeiren M, Gader A, Al-Rasheed S, Bahakim H, Al-Momen A, Al-Salloum A . Coagulopathy of childhood nephrotic syndrome--a reappraisal of the role of natural anticoagulants and fibrinolysis. Haemostasis. 1996; 26(6):304-10. DOI: 10.1159/000217223. View

Schlegel N . Thromboembolic risks and complications in nephrotic children. Semin Thromb Hemost. 1997; 23(3):271-80. DOI: 10.1055/s-2007-996100. View

Hansen J, Svensson B, Olsen R, Ezban M, Osterud B, Paulssen R . Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro. Thromb Haemost. 2000; 83(6):937-43. View

Sandset P, Warn-Cramer B, Maki S, RAPAPORT S . Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized Shwartzman reaction. Blood. 1991; 78(6):1496-502. View

10.

Day K, Hoffman L, Palmier M, Kretzmer K, Huang M, Pyla E . Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit. Blood. 1990; 76(8):1538-45. View

11.

Leurs P, van Oerle R, Wolffenbuttel B, Hamulyak K . Increased tissue factor pathway inhibitor (TFPI) and coagulation in patients with insulin-dependent diabetes mellitus. Thromb Haemost. 1997; 77(3):472-6. View

12.

Palmier M, Hall L, Reisch C, Baldwin M, Wilson A, Wun T . Clearance of recombinant tissue factor pathway inhibitor (TFPI) in rabbits. Thromb Haemost. 1992; 68(1):33-6. View

13.

Bohler T, Linderkamp O, Leo A, Wingen A, Scharer K . Increased aggregation with normal surface charge and deformability of red blood cells in children with nephrotic syndrome. Clin Nephrol. 1992; 38(3):119-24. View

14.

Tkaczyk M, Baj Z . Surface markers of platelet function in idiopathic nephrotic syndrome in children. Pediatr Nephrol. 2002; 17(8):673-7. DOI: 10.1007/s00467-002-0865-7. View

15.

Citak A, Emre S, Sairin A, Bilge I, Nayir A . Hemostatic problems and thromboembolic complications in nephrotic children. Pediatr Nephrol. 2000; 14(2):138-42. DOI: 10.1007/s004670050029. View

16.

RAPAPORT S . The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb Haemost. 1991; 66(1):6-15. View

17.

Svensson P, Dahlback B . Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994; 330(8):517-22. DOI: 10.1056/NEJM199402243300801. View

18.

Kemme M, Burggraaf J, Schoemaker R, Cohen A, Kluft C, Chia S . Local tissue factor pathway inhibitor release in the human forearm. Thromb Haemost. 2003; 89(3):438-45. View

19.

Tsukahara H, Haruki S, Hiraoka M, Hori C, Sudo M . Persistent hypercholesterolaemia in frequently relapsing steroid-responsive nephrotic syndrome. J Paediatr Child Health. 1997; 33(3):253-5. DOI: 10.1111/j.1440-1754.1997.tb01591.x. View

20.

Ariens R, Moia M, Rivolta E, Ponticelli C, Mannucci P . High levels of tissue factor pathway inhibitor in patients with nephrotic proteinuria. Thromb Haemost. 1999; 82(3):1020-3. View